A carregar...
Efficacy and safety of neoadjuvant FOLFIRINOX for borderline resectable pancreatic adenocarcinoma: improved efficacy compared with gemcitabine-based regimen
Borderline resectable pancreatic cancer (BRPC) is a potentially resectable disease but is associated with poorer survival compared to primary resectable disease. There has been no prospective trial that compare the efficacy of FOLFIRNOX and gemcitabine-based regimen for BRPC. Between February 2013 a...
Na minha lista:
Publicado no: | Oncotarget |
---|---|
Main Authors: | , , , , , , , , , , , , , , , , |
Formato: | Artigo |
Idioma: | Inglês |
Publicado em: |
Impact Journals LLC
2017
|
Assuntos: | |
Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5542271/ https://ncbi.nlm.nih.gov/pubmed/28564637 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.17940 |
Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|